Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan.
Colin W HowdenErin E CookElyse SwallowKaren YangHelen GuoCorey PelletierRinu JacobKentaro SuganoPublished in: Therapeutic advances in gastroenterology (2023)
-related HCRU, and lower healthcare costs than patients treated with PPI-based therapy.